- Home
- RGNX vs FTHY Comparison
RGNX vs FTHY Comparison
Compare RGNX & FTHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RGNX | FTHY |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.1M | 500.1M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | RGNX | FTHY |
|---|---|---|
| Price | $8.76 | $13.62 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $28.75 | N/A |
| AVG Volume (30 Days) | ★ 501.7K | 101.6K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 10.93% |
| EPS Growth | ★ 18.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,393,000.00 | N/A |
| Revenue This Year | $51.21 | N/A |
| Revenue Next Year | $19.08 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 126.48 | N/A |
| 52 Week Low | $6.89 | $13.20 |
| 52 Week High | $16.19 | $14.98 |
Technical Indicators
Market Signals| Indicator | RGNX | FTHY |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 52.69 |
| Support Level | $8.68 | $13.27 |
| Resistance Level | $9.29 | $13.78 |
| Average True Range (ATR) | 0.48 | 0.18 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 28.57 | 64.00 |
Price Performance
Historical ComparisonAbout RGNX REGENXBIO Inc.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.
About FTHY First Trust High Yield Opportunities 2027 Term Fund
FIRST TRUST HIGH YIELD OPPORTUNITIES 2027 TERM FUND is a diversified, closed-end management investment company. The investment objective of the fund is to provide current income. The fund invests a majority of its managed assets in high-yield debt securities of any maturity that are rated below investment grade at the time of purchase or unrated securities. Its investment portfolio comprises corporate bonds and notes, senior floating-rate loan interests, foreign corporate bonds and notes, money market funds, and other instruments across various industries.